0001209191-20-009645.txt : 20200214
0001209191-20-009645.hdr.sgml : 20200214
20200214161921
ACCESSION NUMBER: 0001209191-20-009645
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200212
FILED AS OF DATE: 20200214
DATE AS OF CHANGE: 20200214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Do Hung
CENTRAL INDEX KEY: 0001593353
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33497
FILM NUMBER: 20620206
MAIL ADDRESS:
STREET 1: C/O AMICUS THERAPEUTICS, INC.
STREET 2: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001178879
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200422823
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: (609) 662-2000
MAIL ADDRESS:
STREET 1: 1 CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC
DATE OF NAME CHANGE: 20020729
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-12
0
0001178879
AMICUS THERAPEUTICS, INC.
FOLD
0001593353
Do Hung
C/O AMICUS THERAPEUTICS, INC.
1 CEDAR BROOK DRIVE
CRANBURY
NJ
08512
0
1
0
0
Chief Science Officer
Common Stock
2020-02-12
4
M
0
6300
8.61
A
527455
D
Common Stock
2020-02-12
4
M
0
29148
6.10
A
556603
D
Common Stock
2020-02-12
4
M
0
17652
5.13
A
574255
D
Common Stock
2020-02-12
4
S
0
63356
11.0067
D
510899
D
Stock Options (right to buy)
8.61
2020-02-12
4
M
0
6300
0.00
D
2025-01-02
Common Stock
6300
43700
D
Stock Options (right to buy)
6.10
2020-02-12
4
M
0
29148
0.00
D
2026-06-15
Common Stock
29148
6270
D
Stock Options (right to buy)
5.13
2020-02-12
4
M
0
17652
0.00
D
2027-01-03
Common Stock
17652
19133
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.00 to $11.03 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
All of the options were fully vested and exercisable as of February 12, 2020.
As of February 12, 2020, 45,812 options were fully vested and exercisable and 4,188 remained unvested from this grant.
As of February 12, 2020, 20,594 options were fully vested and exercisable and 16,191 remained unvested from this grant.
/s/ Christian Formica, Attorney-in-Fact
2020-02-14